We're watching and we're worried: A future doctor urges med schools to keep teaching inclusiveness
'If physicians are not trained on specific health risks that directly impact transgender patients, how can we provide adequate care? If we are not taught about racial health disparities, how will we work to combat them? If we stop prioritizing inclusion, how can we ensure equal health care for all?' (Getty Images)
When the government puts legal barriers in place to strip away or prevent health care access, it's not just politics — it's real people's lives at stake.
During the summer of 2024, countless transgender and gender expansive patients expressed to me fears about what might happen to their access to gender affirming medical care if a conservative administration were to win the White House. This worst-case scenario became reality in the first weeks of 2025, when President Donald Trump signed an executive order redefining legal gender identity as a strict binary of male and female — effectively erasing recognition of nonbinary and transgender individuals and interrupting federal funding to institutions providing gender-affirming health care.
As a transgender health program intern, I have seen providers try to reassure patients of their well-being and safety while they themselves fear how their job will be affected if the laws would drastically alter the way we practice medicine.
As a gay man about to enter the medical profession, I am afraid. The recent wave of anti-trans initiatives pushed by this administration is part of a much broader effort to dismantle diversity, equity, inclusion, and belonging (DEIB) programs across the country under the guise of 'restoring meritocracy' and 'leveling the playing field.' But in health care, the playing field has never been level. Minority populations continue to face disproportionate health risks and barriers to care.
DEIB is the foundation of medical education. It teaches future physicians how to address these disparities and combat the structural inequities that put vulnerable patients at risk. Studies show medical students have felt unprepared to manage transgender and gender expansive patients upon graduation. One study even claimed that only 27% of students were confident in their knowledge of the health needs of transgender patients. Beyond that, they could not correctly answer questions about race-related medical history despite affirming that understanding historical context is important in medicine. This lack of education was always a problem, and efforts were underway to solve it. Eliminating DEIB would not only erode this progress but set us back behind where we were even before we started.
In 2020, the American Association of Medical Colleges (AAMC) rolled out the Structural Competency Curriculum which aims to train providers 'to recognize and respond to the impact of upstream, structural factors on patient health and health care.' Since then, medical schools around the country have adopted the values of this curriculum and incorporated it throughout the course of their students' training. Health equity is a core pillar of medical students' professional development and should be embedded into the culture of patient-centric care.
When DEIB is dismantled, programs like these disappear, and awareness of health disparities among marginalized patient populations fades from the culture of those whose job is to provide the proper care and treatment.
If physicians are not trained on specific health risks that directly impact transgender patients, how can we provide adequate care? If we are not taught about racial health disparities, how will we work to combat them? If we stop prioritizing inclusion, how can we ensure equal health care for all?
Everyone deserves to be treated with respect and dignity. Legislation cannot change a person's identity, but it will change their access to health care. Medical schools need to teach this, and we as students want to learn.
Future doctors like me are watching everything that is happening, and we are worried. When students apply to medical school, the number one question they are asked is, 'Why medicine?' While the answer to this question can take many different forms, the bottom line is pretty simple: We want to help people. Medical schools can make a monumental difference in how future doctors navigate this political environment and provide care to patients. We urge medical schools to keep teaching us how to do that for all patients.
New Hampshire Bulletin is part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity. New Hampshire Bulletin maintains editorial independence. Contact Editor Dana Wormald for questions: info@newhampshirebulletin.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
30 minutes ago
- Yahoo
Analysts assess the potential impact of Trump's surprise 50% steel tariffs
-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods
Yahoo
an hour ago
- Yahoo
FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal
The FTSE 100 (^FTSE) and European stocks slipped on Monday as China said the US "severely violated" the terms of their recent trade truce. Chinese officials said they would take strong measures to defend the country's interests. The two countries recently agreed to a 90-day moratorium after talks in Geneva, pledging to lower the tariffs on each other's goods. The US lowered its levy on imports from 145% to 30%, while China dropped its import tariff from 125% to 10%. China said the US had "seriously undermined" the agreement. The comments come after US president Donald Trump said on Friday that China had "totally violated its agreement with us". Beijing said violations included the US blocking sales of computer chip design software to Chinese companies and warning against the use of Chinese computer chips made by companies such as Huawei. They also said the US had cancelled visas for Chinese students. London's premier index fell 0.3%, having opened higher. Defence contractor Babcock International (BAB.L) rose the most, as the UK announced plans to build up a fleet of 12 attack submarines. Germany's DAX (^GDAXI) fell slightly, while the CAC 40 (^FCHI) was 0.2% lower. The pan-European STOXX 600 (^STOXX) was down 0.1%. Last week, Europe agreed its own stay of execution in trade negotiations with the US, pushing back the implementation of a 50% import tariff to July while talks continue on a possible deal. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
an hour ago
- Newsweek
China Accuses Trump of Violation, Threatens 'Forceful Measures'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. China accused the U.S. of violating an agreement made at their tariff-cutting discussions in Geneva in May, and said it will take further action as the trade dispute between the world's two largest economies blows open again. President Donald Trump's administration has in recent days issued AI chip export control guidelines, stopped the sale of chip design software to China, and is planning to revoke a significant number of Chinese student visas. Trump had also accused the Chinese side of having "TOTALLY VIOLATED" the Geneva agreement, which saw the U.S. and China both reduce their import tariffs by 115 percentage points, soothing global markets. "These practices seriously violate the consensus" reached in Geneva, the Chinese Commerce Ministry said in a statement on Monday. The Commerce Ministry said China held up its end of the deal, canceling or suspending tariffs and non-tariff measures taken against the U.S. "reciprocal tariffs" following the agreement. "The United States has unilaterally provoked new economic and trade frictions, exacerbating the uncertainty and instability of bilateral economic and trade relations," while China has stood by its commitments, the statement said. It also threatened unspecified retaliation, saying China will "continue to take resolute and forceful measures to safeguard its legitimate rights and interests." And in response to recent comments by Trump, it said of the U.S.: "Instead of reflecting on itself, it has turned the tables and unreasonably accused China of violating the consensus, which is seriously contrary to the facts." This is a developing article. Updates to follow. This article includes reporting by The Associated Press.